DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

This is a Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer following standard of care treatment with chemotherapy and immunotherapy.

Trial Details

NCT ID
NCT07249372
Phase
PHASE2
Sponsor
NYU Langone Health
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • DRP-104
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Signed informed consent form
  • 18 years of age or older
  • Diagnosis of advanced or recurrent, histologically or cytologically confirmed metastatic or unresectable non-small cell lung cancer harboring NFE2L…
  • Patients must have Response Evaluation Criteria in Solid Tumors (RECIST) measurable lesions

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →